Nachrichten zur Nanoviricides Inc. Aktie

NanoViricides prepares for Phase II trials for antiviral NV-387

NanoViricides (NYSE-A:NNVC) filed its annual report, announcing that its broad-spectrum antiviral NV-387 is progressing to Phase II clinical trials, with...…

NanoViricides expands antiviral drug pipeline with TheraCour Pharma agreement

NanoViricides (NYSE-A:NNVC) announced that it has signed a Memorandum of Understanding (MOU) with TheraCour Pharma, granting it the right of…

NanoViricides CEO talks lead drug asset’s potential as MPOX therapy

NanoViricides (NYSE-A:NNVC) CEO Anil Diwan joined Proactive to discuss the promise of its lead drug NV-387 as a broad-spectrum antiviral.…

NanoViricides exploring emergency protocol to evaluate NV-387 for MPOX

NanoViricides (NYSE-A:NNVC) announced that it is investigating the potential use of its lead drug candidate NV-387 to treat MPOX patients…

NanoViricides prepares for Phase II trial of broad-spectrum antiviral NV-387

NanoViricides (NYSE-A:NNVC) is advancing its clinical program with plans for an innovative Phase II trial of its drug candidate NV-387,…

NanoViricides reports major progress in advancing broad-spectrum antiviral drug NV-387

NanoViricides (NYSE-A:NNVC) has highlighted significant progress made in advancing its lead drug candidate NV-387 during the 2024 fiscal year 2024,…

NanoViricides’ lead asset for broad spectrum efficacy wins praise in industry reports

NanoViricides (NYSE-A:NNVC) has announced the publication of two independent reports on the company by industry analysts which highlight the potential…

NanoViricides’ lead asset with broad spectrum efficacy represents paradigm shift: analysts

NanoViricides (NYSE-A:NNVC)’ broad spectrum drug candidate NV-387 could present “a new paradigm shift in viral therapy,” according to a new…

NanoViricides’ lead asset for broad spectrum efficacy represents paradigm shift: analysts

NanoViricides (NYSE-A:NNVC) has announced the publication of two independent reports on the company by industry analysts which highlight the potential…

NanoViricides spotlights lead drug candidates potential as COVID therapy

NanoViricides (NYSE-A:NNVC) has highlighted the strong safety and efficacy of its lead clinical drug candidate NV-387 against coronaviruses. Animal studies...…

NanoViricides discusses lead program and next steps

NanoViricides (NYSE-A:NNVC), a leader in broad-spectrum antiviral nanomedicines, is advancing its development program for NV-387. This single drug has shown...…

NanoViricides hails broad potential of lead antiviral drug as it prepares to begin first Phase II trial

NanoViricides (NYSE-A:NNVC), a specialist in broad-spectrum antiviral medicines, highlighted the efficacy of its lead drug, NV-387 against a range of...…

NanoViricides hails the potential of NV-387 in combatting bird flu virus H5N1

NanoViricides (NYSE-A:NNVC), a specialist in broad-spectrum antiviral medicines, believes its drug NV-387 could be crucial in fighting the bird flu…

NanoViricides says antiviral drug candidate shows promise in protecting lungs against Influenza A

NanoViricides (NYSE-A:NNVC) announced that its ultra-broad-spectrum antiviral drug candidate NV-387 demonstrated effectiveness in protecting lungs from...…

NanoViricides antiviral candidate may be first effective oral nanomedicine

NanoViricides (NYSE-A:NNVC) said its lead antiviral candidate, NV-387, was found to be highly active when taken orally, making potentially the first...…

NanoViricides says lead asset exhibits desirable blood concentration profile for infrequent dosing

NanoViricides (NYSE-A:NNVC) has unveiled additional positive data for its lead clinical-stage broad-spectrum antiviral agent NV-387, a desirable blood...…

NanoViricides CEO says lead asset NV-387 could be ‘holy grail’ of antiviral medicines

NanoViricides (NYSE-A:NNVC) is developing a first-in-class, broad-spectrum anti-viral agent NV-387 that it believes could revolutionize the treatment of...…

NanoViricides taps Aagami to seek out licensing and partnership opportunities

NanoViricides (NYSE-A:NNVC) announced that it has engaged Chicago-based life sciences consultancy firm Aagami for business development, specifically to seek...…

NanoViricides could generate ‘antiviral superdrug’ for multiple diseases, analysts believe

NanoViricides (NYSE-A:NNVC) has been awarded a ‘Buy’ rating and $6.50 price target by analysts at EF Hutton following the release…

Novel anti-viral could boost a US$3 bln market

New focus on viral respiratory infections especially highly transmissible RSV NanoViricides (NYSE-A:NNVC) (NV), a US company, owns a novel, multi-target,...…

NanoViricides reports strong antiviral activity of NV-387 against RSV

NanoViricides (NYSE-A:NNVC) has reported that its antiviral drug candidate NV-387 demonstrated significant efficacy against respiratory syncytial virus...…

NanoViricides shares gain as new data shows lead drug assets strong activity against RSV

NanoViricides (NYSE-A:NNVC) has released new data which shows the strength of the antiviral activity of its lead drug asset NV-387…

NanoViricides unveils new data showing lead drug asset’s strong activity against RSV

NanoViricides (NYSE-A:NNVC) has released new data which shows the strength of the antiviral activity of its lead drug asset NV-387…

NanoViricides CEO discusses NV-387’s broad-spectrum antiviral potential

NanoViricides (NYSE-A:NNVC) has released a slew of new data supporting the safety and ultra-broad antiviral activity of its investigational therapeutic...…

NanoViricides to showcase lead drug asset’s progress at EF Hutton Annual Global Conference

NanoViricides (NYSE-A:NNVC) announced that members of its leadership team will be attending the EF Hutton Annual Global Conference being held…

NanoViricides to showcase lead drug asset’s progress at global conference

NanoViricides (NYSE-A:NNVC) announced that members of its leadership team will be attending the EF Hutton Annual Global Conference being held…

NanoViricides says lead asset shows antiviral activity against Smallpox and Mpox

NanoViricides (NYSE-A:NNVC) told investors that the ultra-broad antiviral activity spectrum of its lead drug asset NV-387 includes activity against the...…

NanoViricides drug asset shows ‘superior antiviral effects’ against Influenza A

NanoViricides (NYSE-A:NNVC) announced that its lead drug asset NV-387 has shown ultra-broad antiviral activity, including against Influenza A viruses.   The...…

NanoViricides completes Phase 1 trial of lead asset NV-387

NanoViricides (NYSE-A:NNVC) announced that a Phase 1 trial of its investigational therapeutic NV-387 has been completed. The company, a leader…

NanoViricides completes Phase 1 trial for respiratory viral infection candidate

NanoViricides (NYSE-A:NNVC) announced that a Phase 1 trial of its investigational therapeutic NV-387 has been completed. The company, a leader…

NanoViricides boosts liquidity measures and manufacturing capacity to support clinical trials

NanoViricides (NYSE-A:NNVC) said it is making good progress in its antiviral drug development program, with strong safety data for its…

Pioneering nanomedicine: NanoViricides making big strides fighting viral infections

NanoViricides (NYSE-A:NNVC) has a platform that shows a versatile and effective approach to antiviral therapy, with potential applications that target…

NanoViricides highlights lead asset NV-387’s potential to revolutionize the treatment of antiviral infections

NanoViricides (NYSE-A:NNVC) told investors it believes that the strong safety and tolerability of its NV-CoV-2 oral drug products containing the…

NanoViricides says lead asset NV-387 could revolutionize antiviral treatment

NanoViricides (NYSE-A:NNVC) told investors it believes that the strong safety and tolerability of its NV-CoV-2 oral drug products containing the…

NanoViricides’ potential to address dozens of diseases highlighted by analysts following trial success

NanoViricides (NYSE-A:NNVC) has earned a ‘Buy’ rating and a $6.50 price target from EFHutton analysts after the company released positive…

NanoViricides’ potential to address dozens of diseases highlighted following trial success

NanoViricides (NYSE-A:NNVC) has earned a ‘Buy’ rating and a $6.50 price target from EF Hutton analysts after the company released…

NanoViricides announces key data on Ultra-Broad-Spectrum Antiviral Drug NV-CoV-2

…

NanoViricides successfully concludes first-in-human study

Drug developer NanoViricides (NYSE-A:NNVC) Inc said it has successfully completed its phase Ia/Ib clinical trial of NV-CoV-2, its lead asset....…

NanoViricides makes progress as it completes dosing in Phase 1a COVID study

…

NanoViricides updates progress on Phase 1a/1b clinical trial of antiviral drug candidate NV-387

…

NanoViricides completes Phase 1a/1b human clinical trial for its broad-spectrum antiviral drug

NanoViricides (NYSE-A:NNVC) has successfully wrapped up the first phase of a human clinical trial for its broad-spectrum antiviral drug, NV-CoV-2.…

NanoViricides continues to progress antiviral drug candidate NV-CoV-2 in 3Q

NanoViricides (NYSE-A:NNVC) said it exited the third quarter with enough cash on hand to progress clinical trials involving its lead…

NanoViricides drug candidate found to be ‘highly effective’ for MPox and Smallpox in animal trial

NanoViricides (NYSE-A:NNVC) has announced that its broad-spectrum antiviral drug candidate NV-387 in development for MPox and Smallpox was shown to…

NNVC: NanoViricides Begins Clinical Trial of NV-CoV-2

By David Bautz, PhD AMEX:NNVC In June 2023, NanoViricides, Inc. (AMEX:NNVC) announced the initiation of a Phase 1a/b safety and efficacy clinical…

NanoViricides progressing well with new Covid study | NYSE-A:NNVC

Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...…

NanoViricides creating special purpose nanomaterials for antiviral therapy

Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...…

NanoViricides Shares Surge on NV-387 Showing in RSV >NNVC

NanoViricides Shares Surge on NV-387 Showing in RSV >NNVC...…

NanoViricides, Inc.: Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs

SHELTON, CO / ACCESSWIRE / July 6, 2023 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") reports that the clinical trial…

NanoViricides, Inc.: NanoViricides Announces that Clinical Trials of Its Broad-Spectrum Antiviral Drug NV-CoV-2 Have Begun

SHELTON, CT / ACCESSWIRE / June 29, 2023 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") reports that clinical trials of…

NanoViricides, Inc. to Present at the BIO International Convention in Boston on June 5th, 2023 at 3:15pm ET

SHELTON, CT / ACCESSWIRE / May 31, 2023 / NanoViricides, Inc. (NYSE Amer:NNVC) (the "Company"), announces that the Companys President,…